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Abstract
Aims: The aims of this study were to explore the development of bacterial
resistance and cross-resistance in four common human pathogens following
realistic exposure to antibiotics found in over-the-counter (OTC) sore throat
medicines: gramicidin, neomycin, bacitracin and tyrothricin.
Methods and Results: Bacterial exposure to in-use (concentration in the
product before use) and diluted concentration (i.e. during use) of antibiotic
where conducted in broth for 24 h or until growth was visible. The changes in
bacterial susceptibility profile before and after exposure was determined using
standardized ISO microdilution broth. Antibiotic testing was performed
according to EUCAST guidelines. We demonstrated that test bacteria were able
to survive exposure to the in-use concentrations of some antibiotics used in
OTC medicines. Exposure to during use concentrations of bacitracin resulted
in stable increase in minimal inhibitory concentration (MIC) (>8-fold) in
Staphylococcus aureus and Acinetobacter baumannii. Exposure to tyrothricin
resulted in a stable increase in MIC (24-fold) in Klebsiella pneumoniae, and
exposure to neomycin resulted in a stable increase MIC (5000-fold higher than
the baseline) in Streptococcus pyogenes. Clinical cross-resistance to other
antibiotics (ciprofloxacin, fusidic acid, gentamicin, cefpodoxime,
amoxicillin/clavulanic acid and cefotaxime) was also demonstrated following
exposure to bacitracin or tyrothricin. Bacitracin exposure lead to a stable
bacterial resistance after 10 passages.
Conclusions: Our results indicate that OTC antibiotic medicines have the
potential to drive resistance and cross-resistance in vitro.
Significance and Impact of the Study: Tackling antibiotic resistance is a high
worldwide priority. It is widely accepted that the overuse and misuse of
antibiotics increase the risk of the development and spread of antibiotic
resistance within communities. A number of OTC sore throat products, widely
available across the world for topical use in respiratory indications, contain
locally delivered antibiotics. Our findings showed that these antibiotics in OTC
medicines present a risk for emerging cross-resistance in a number of bacterial
respiratory pathogens.
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Introduction
The chemotherapeutic treatment of pathogens is increas-
ingly arduous as antibiotic resistance becomes more preva-
lent. Currently, 700 000 deaths per year are attributed to
antibiotic resistant diseases and this is expected to rise to
10 million by 2050 (IACG 2019). Alongside alarming fig-
ures of attributed deaths, antibiotic resistance has a wider
bearing on our economy. It is predicted that by 2030,
antimicrobial resistance could force up to 24 million peo-
ple into extreme poverty due to its heavy impact on the
economy (IACG 2019). In part, the misuse and over-use of
antibiotics are driving factors in emerging resistance
(Wright 2014). Around 80% of sore throat cases have a
viral aetiology (M€akel€a et al. 1998; Ebell et al. 2000; Worrall
2007; Worral 2008) and, even when the infection is bacte-
rial, most cases resolve without antibiotics (Bisno 2001;
Pelucchi et al. 2012; Spinks et al. 2013). The National Insti-
tute for Health and Care Excellence (NICE) recommends
that no antibiotics be provided for upper and lower respi-
ratory tract infection if the patient is not systemically
unwell or at higher risk of complications (NICE 2019). The
imprudent use of antibiotics can also decrease human
immunity to a level that poses a risk of and increased sus-
ceptibility to subsequent disease (Keeney et al. 2014). A
review of six studies of the common cold and five studies
of acute purulent rhinitis suggested that antibiotics do not
work for either the common cold or for acute purulent
rhinitis and many people are affected by antibiotic side
effects (Kenealy and Arroll 2013). Around 75% of all
antibiotic prescribing is estimated to take place in the com-
munity setting of primary care (Zuckerman et al. 2007), of
this, respiratory tract infections account for 60% (Tan et al.
2008). Nonetheless, the over-prescription of antibiotics still
occurs with an estimated 20% of all primary care antibiotic
prescriptions being deemed inappropriate (PHE 2017).
Additionally, in 2016 it was estimated that 7% of antibiotic
consumed in the EU are done so without a prescription
(Johnson et al. 2018). Greece, Romania and Cyprus are the
EU member states with the highest use of antibiotics with-
out prescription, mainly driven by over the counter (OTC)
retailing with 80–100% being obtained in a pharmacy
(Paget et al. 2017). Antibiotic resistance is reported to be
higher in countries that have a greater use of antibiotics
(EARS 2017). While there is a significant body of evidence
on resistance development to systemic antibiotics which
are primarily restricted to dispensing with a prescription,
very little data exist on topical antibiotics dispensed OTC
for conditions like sore throat (Essack et al. 2019).
This study aims to (i) understand the development of
bacterial resistance in nine common human pathogens to
four locally delivered antibiotics (gramicidin, neomycin,
bacitracin and tyrothricin) found in some OTC sore
throat medicines, and (ii) measure possible emerging
cross-resistance to different classes of antibiotics following
during use exposition to these OTC antibiotics.
Methods
Test antibiotics
Gramicidin and tyrothricin were purchased in powder
form (Xellia Pharmaceuticals ApS, Copenhagen, Den-
mark), and neomycin and bacitracin were kindly pro-
vided by Reckitt Benckiser (Slough, UK). Gramicidin and
tyrothricin were initially solubilized in 100% DMSO and
then diluted into 50% DMSO; the final test concentration
of DMSO was no more than 5% which was shown not to
affect bacterial viability (ISO 2006).
Micro-organisms
Bacteria investigated in this study were as follows: Staphy-
lococcus aureus ATCC 6538, Streptococcus pneumoniae
ATCC 49619, Streptococcus pyogenes ATCC 19615, Acine-
tobacter baumannii ATCC 19568, Enterobacter cloacae
1781, Escherichia coli ATCC 25922, Haemophilus influen-
zae ATCC 10211, Klebsiella pneumoniae ATCC 13883 and
Pseudomonas aeruginosa ATCC 27853. Bacterial cultures
were inoculated onto Mueller-Hinton agar (MHA) for
24 h (37°C) and then sub-cultured into Mueller-Hinton
broth (MHB) and incubated for another 24 h at 37°C.
Streptococcus pneumoniae was incubated in 5% CO2. All
working cultures were centrifuged at 5000 g and re-sus-
pended in tryptone-sodium chloride diluent (TSC;
1 g l1 tryptone and 85 g l1 sodium chloride) and an
optical density (OD600nm) equivalent to 10
6 CFU per ml
was obtained following appropriate dilution in TSC.
All cultures obtained after antibiotic exposure were fro-
zen and stored at 80°C for further testing. Purity of
suspensions and homogeneity were checked using the
Gram-staining technique and selective media.
Test protocol
A simple protocol based on the in-use antibiotic concen-
trations of the four commercially available OTC antibi-
otics was used (Figure 1). The in-use concentration of
antibiotic is subjected to dilution during use of the pro-
duct; here a decrease in concentration resulting from the
dilution of product in saliva.
Antibiotic susceptibility testing
Initially, baseline minimal inhibitory concentration
(MIC) data were obtained using the ISO [20776-1]
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microdilution broth standard (ISO 2006). Briefly, antibi-
otics were diluted in MHB in halving concentrations
along a 96-well plate. Standardized overnight bacterial
cultures (106 CFU per ml) were added to each well and
incubated for 24 h at 37°C. Despite the inclusion
of DMSO, tyrothricin and gramicidin produced a
cloudy solution, for this reason, following incubation, vis-
ible growth was recorded and 20 ll of each well
suspension was plated onto an MHA plate, which was
incubated for 24 h at 37°C. The MIC was considered the
highest concentration in which no visible growth was
observed.
Antibiotic cross-susceptibility testing
Antibiotic susceptibility was tested with the disc diffusion
method in accordance with the European Committee on
Antimicrobial Susceptibility Testing (EUCAST 2019) pro-
tocol. Briefly, bacterial suspensions (05 Mcfarland stan-
dard) were applied to an MHA plate and spread evenly
using a sterile cotton swab (Fisher Scientific, Loughbor-
ough, UK). The antibiotic discs (Beckton Dickinson,
Wokingham, UK) were placed onto the agar surface and
plates were incubated (24 h; 37°C). Following incubation,
zone diameters of growth inhibition were recorded and
compared to EUCAST breakpoints (EUCAST 2019) to
confirm clinical susceptibility. To investigate for antibi-
otic cross-resistance following exposure to the test
antibiotics, the bacteria were tested against a panel of 6–8
EUCAST recommended antibiotics from different classes
(Table 1). Baseline antibiotic susceptibility profiles and
clinical resistance status of tested isolates are presented in
Table S1.
Investigating the ability for bacteria to grow in during-
use antibiotic concentration
A number of different concentrations were tested to rep-
resent dilutions of antibiotic concentrations when OTC
products are used. Examples of brand named medicines
containing a range of in-use antibiotic concentrations are
provided in Table S2. The selected ‘in-use’ concentration
used in this study represented a compromised concentra-
tion used in these products and did not intend to repre-
sent each of the product listed. The original in-use
concentrations that were subsequently diluted were as fol-
lows: gramicidin 3 mg ml1, neomycin 25 mg ml1,
bacitracin 100 units, tyrothricin 4 mg ml1. Test bacteria
were exposed to the antibiotics for an initial exposure
time of 24 h at 37°C under constant agitation. If no
microbial growth was observed after 24 h, incubation was
continued for a maximum of 7 days and the time taken
until visible growth was observed as the ‘initial exposure
time’. If no growth occurred after 7 day exposure, lower
concentrations were investigated successively until growth
was observed: 90, 75, 50, 25, 10, 5 and 1%.
Figure 1 Protocol to study the impact of antibiotic exposure on emerging resistance following the use of the OTC products.
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Phenotype stability for bacteria surviving in-use
antibiotic exposure
Following 24 h exposure to the in-use concentration of
an antibiotic, surviving bacteria were passaged into tubes
containing broth and the antibiotic at the in-use concen-
tration. Briefly, the exposure suspension was centrifuged
(5000 g; 10 min) and re-suspended in TSC diluent and
an OD600nm equivalent to 10
6 CFU per ml was obtained
through appropriate dilution. One hundred microlitre of
the washed suspension was added to a fresh tube of
MHB containing the appropriate concentration of the rel-
evant antibiotic and incubated for 24 h at 37°C. A maxi-
mum of 10 passages were performed. MIC and EUCAST
tests were conducted after the 1st, 5th and 10th expo-
sures.
Results
Antibiotic susceptibility testing
Baseline MIC values were predominantly below the level
covered by the in-use concentration of the antibiotics.
The exceptions were S. aureus, A. baumannii and E. coli
with gramicidin and K. pneumoniae with neomycin
(Table 2). Despite the MIC value being lower than the
in-use exposure concentration, there were instances of
bacterial growth at the in-use concentration. Pseudomonas
aeruginosa grew at 4 mg ml1 (100% of selected in-use
concentration) tyrothricin after 24 h incubation. This
exposure resulted in a shift in MIC value from
25 mg ml1 (baseline value) to >5 mg ml1 (Table 2).
This twofold increase (Table 3) was however no longer
observable after five passages both in the presence of
4 mg ml1 tyrothricin and broth only. Klebsiella pneumo-
niae and A. baumannii grew in the presence of tyrothricin
at 4 mg ml1 (100% of selected in-use concentration)
and 04 mg ml1 (10% of selected in-use concentration)
respectively. These exposures did not result in a change
to MIC value after the initial exposure or after 10 pas-
sages with or without antibiotic. Staphylococcus aureus
grew in the presence of 100 U bacitracin (100% of pro-
posed in-use concentration) after 144 h incubation and
became less susceptible to the antibiotic with a fourfold
increase (Table 3) in MIC from 318 U (baseline value)
to 125 U (Table 4). Streptococcus pyogenes grew in the
presence of 0125 mg ml1 (5% of selected in-use con-
centration) neomycin after 144 h. This exposure resulted
in a 125-fold increase of the baseline MIC; from
0005 mg ml1) to 063 mg ml1 (Table 4). Further-
more, after one passage in the presence of neomycin
(0125 mg ml1), the MIC increased to 25 mg ml1,
which was sustained over 10 passages (Table 4). When
neomycin was removed and S. pyogenes was passaged in
broth only, the MIC decreased to 016 mg ml1
(Table 4), which was still 36-fold higher than the baseline
MIC (Table 3). The MIC of 016 mg ml1 was stable
over 10 passages.
Antibiotic cross-resistance
There were instances where exposure to the in-use con-
centration of an antibiotic affected the clinical susceptibil-
ity profile of different antibiotics from sensitive to
resistant (Table 5). Staphylococcus aureus became resistant
to ciprofloxacin after one passage in bacitracin, this
change was not observed at passage 5–10. Staphylococcus
aureus was resistant to ciprofloxacin, fusidic acid and
gentamicin after one passage in 100 U bacitracin, this
change was also not observed at passage 5–10. Klebsiella
pneumoniae became clinically resistant to cefpoxidime,
amoxicillin-clavulanic acid and cefotaxime after one pas-
sage in 4 mg ml1 tyrothricin. This change in susceptibil-
ity profile was not observed in passages 5 and 10 when
passaged in broth only. However, with the consistent
presence of 4 mg ml1 tyrothricin K. pneumoniae
demonstrated stable cross-resistance over 10 passages.
Table 1 EUCAST recommended antibiotic discs tested for each strain
Strain Antibiotics used in EUCAST test
Staphylococcus
aureus
Benzylpenicillin, cefoxitin, ciprofloxacin,
gentamicin, erythromycin, tetracycline,
chloramphenicol, fusidic acid
Streptococcus
pneumoniae
Benzylpenicillin, levofloxacin, vancomycin,
erythromycin, tetracycline, chloramphenicol,
trimethroprim-sulfamethoxazole
Streptococcus
pyogenes
Benzylpenicillin, levofloxacin, vancomycin,
erythromycin, tetracycline, chloramphenicol,
rifampicin
Acinetobacter
baumannii
Trimethoprim, levofloxacin, ciprofloxacin,
gentamicin, tobramycin
Enterobacter
cloacae
Co-amoxiclav, piperacillin/tazobactam,
cefotaxime, imipenem, ciprofloxacin, fusidic
acid
Escherichia coli Co-amoxiclav, piperacillin/tazobactam,
cefotaxime, imipenem, ciprofloxacin, fusidic
acid
Haemophilus
influenzae
Ampicillin, cefotaxime, imipenem, ciprofloxacin,
erythromycin, tetracycline, colistin
Klebsiella
pneumoniae
Cefpodoxime, ceftazidime, co-amoxiclav,
cefotaxime, ciprofloxacin, gentamicin,
piperacillin/tazobactam, piperacillin
Pseudomonas
aeruginosa
Ciprofloxacin, cefepime, ceftazidime,
gentamicin, imipenem, piperacillin, piperacillin/
tazobactam, tobramycin
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Discussion
This study established the ability for five common human
pathogens (S. aureus ATCC 6538, A. baumannii ATCC
19568 and S. pyogenes ATCC 19615, K. pneumoniae, P.
aeruginosa to survive a range of concentrations of several
antibiotics used in topical OTC sore throat products, and
to become less susceptible to these antibiotics and clini-
cally resistant to unrelated ones. Clinical resistance to
other antibiotics was demonstrated following exposure to
tyrothricin and bacitracin, with resistance sustained after
10 passages following tyrothricin exposure. Streptococcus
pyogenes is the most common bacterial cause of sore
throat illness and is knows to be broadly sensitive to
penicillin, which is used as a first-line treatment for con-
firmed infection. The observed development of S. pyoge-
nes resistance to neomycin is concerning as this antibiotic
is widely used systemically, that is, for intestinal disease
(Basseri et al. 2011).
The in-use concentration can be defined as the concen-
tration of an active that is applied through disinfection.
The in-use concentration may be diluted throughout the
disinfection process leading to the term ‘during-use’ con-
centration as discussed in previous works (Knapp et al.
2015; Wesgate et al. 2016). The probability for low con-
centrations of antibiotic to affect a decrease in suscepti-
bility is a concern as OTC antibiotic medicines
commonly encounter a dilution effect due to the amount
of saliva and mucus naturally produced in the area of
intended application. The uncontrolled and indiscrimi-
nate use of locally applied antibiotics like tyrothricin for
sore throat is cited to not be of clinical concern due to
the absence of resistance (Strauss-Grabo et al. 2014);
however, the study confirms that as with systemic antibi-
otics, locally applied antibiotics do lead to the develop-
ment of antibiotic resistance and more concerningly,
cross-resistance to those antibiotics used systemically to
treat life-threatening infections. The protocol used in this
study cannot reproduce exactly the in situ fate of antibi-
otics in OTC products when taken. Even where lower
concentrations were used to mimic product dilution
upon usage, contact time between a pathogen and the
Table 2 MIC values before (baseline) and after exposure to antibiotics. Refer to the text for selected in-use concentration and percentage expo-
sure time
Tyrothrycin (mg ml1)
(in-use concentration
percentage/exposure time)
Gramicidin (mg ml1)
(in-use concentration
percentage/exposure
time)
Bacitracin (units)
(in-use concentration
percentage/exposure
time)
Neomycin (mg ml1)
(in-use concentration
percentage/exposure
time)
Baseline Exposure Baseline Exposure Baseline Exposure Baseline Exposure
Staphylococcus aureus 0008 NG (1%/168 h) >30 >30 (100%/
144 h)
3125 125 (100/
144 h)
0002 NG (1%/168 h)
Streptococcus
pneumoniae
<0001 NG (1%/168 h) <004 NG (1%/168 h) <006 NG (1%/168 h) <0003 NG (1%/168 h)
Streptococcus pyogenes 0002 NG (1%/168 h) 0000006 NG (1%/168 h) 0004 NG (1%/168 h) 0005 063 (5%/
144 h)
Acinetobacter baumannii 2 2 (10&5%/24 h)
*
>30 >30 (100%/24 h) 3125 125 (5%/
24 h)†
<25 <25 (5%/
24 h)‡
Enterobacter cloacae 1 NG (1%/168 h) 15 NG (1%/168 h) 625 NG (1%/168 h) 0006 NG (1%/168 h)
Escherichia coli 167 NG (1%/168 h) >30 NG (1%/168 h) 195 NG (1%/168 h) 0006 NG (1%/168 h)
Haemophilus influenzae 003 NG (1%/168 h) 0004 NG (1%/168 h) 098 NG (1%/168 h) 0003 NG (1%/168 h)
Klebsiellapneumoniae 104 002 (100%/
24 h)
625 NG (1%/168 h) 391 NG (1%/168 h) 312 NG (1%/168 h)
Pseudomonas
aeruginosa
25 >5 (100%/24 h) 30 30 (100%/24 h) 781 NG (1%/168 h) 012 NG (1%/168 h)
Bold text represents MIC that are higher than the ‘in-use’ concentration; text not in bold represents MIC phenotype that was lower than or equal
to the ‘in-use’ concentration.
NG, no recoverable growth after initial exposure after 7 days incubation in 1% of in-use concentration.
*After growth of A. baumannii at 10 and 5% in 24 h, no further growth was observed.
†The change in MIC resulting from 24 h exposure of 5% bacitracin occurred in only one of three repeats.
‡The change in MIC resulting from 24 h exposure of 5% neomycin occurred in only one of three repeats.
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antibiotic in situ would be difficult to predict. In vitro
study relies on setting and controlling set test parameters
to improve result reproducibility, and ultimately provide
reliable information on a potential risk associated with,
in this case, antibiotic usage.
There is a direct link between antibiotic consumption
and antimicrobial resistance (Bell et al. 2014). At very
high concentrations, antibiotics apply a selective pressure
that is fatal to susceptible micro-organisms therefore
allowing resistant organisms to survive and replicate to
form a dominant population (Wistrand-Yuen et al.
2018). Even very low (sub-lethal) concentrations of an
antibiotic can produce a selective pressure that favours
adaption (Gullberg et al. 2011, 2014; Liu et al. 2011; San-
degren 2014). Transient changes in antibiotic susceptibil-
ity, as seen in the case of S. aureus resistance to CIP, FA
and CN after bacitracin exposure, suggest metabolic regu-
lations that govern defence mechanisms such as efflux
mechanisms and changes in the structure of the cell
membrane to alter permeability (Tezel and Pavlostathis
2015). Stable changes in susceptibility, however, suggest
genetic mutations that confer to newly acquired resis-
tance that may be inherited by future generations (Meyer
and Cookson 2010; Tezel and Pavlostathis 2015). The
probability for low concentrations of an antibiotic to
affect a stable decrease in susceptibility is a concern as
OTC antibiotic medicines commonly encounter a dilu-
tion effect due to the amount of saliva and mucus natu-
rally produced in the area of intended application.
The lag phase is when micro-organisms react to the
environment around them and adapt to stressful influ-
ences (Rolfe et al. 2012). Here, the expression or resis-
tance mechanisms that aim to decrease the detrimental
concentration of an antimicrobial to a level that does not
interfere with bacterial growth may be associated with an
extended lag phase. The lag phase has been associated
with primary metabolic changes that lead to increased
drug tolerance (Fridman et al. 2014). There were
instances where growth while in the presence of antibiotic
was observed after just 24 h incubation. It has been
Table 3 Fold changes in MIC after exposure and passage in antibiotics or broth only. Values in bold represents an MIC higher than the baseline
MIC
Fold changes
Tyrothricin Gramicidin Neomycin Bacitracin
Antibiotic Broth only Antibiotic Broth only Antibiotic Broth only Antibiotic Broth only
Staphylococcus aureus
144 h NT NT No change NT NT 4
P1 8 4
P5 >8 2
P10 >8 2
Streptococcus pyogenes
144 h NT NT NT NT 125 NT NT
P1 5000 32
P5 5000 32
P10 5000 32
Acinetobacter baumannii
24 h No change No change No change 4
P1 No growth 8 8
P5 8 8
P10 8 8
Klebsiella pneumoniae
24 h 52* NT NT NT NT NT NT
P1 2 24
P5 2 24
P10 2 24
Pseudomonas aeruginosa
24 h 2 No change NT NT NT NT
P1 No growth
P5
P10
144 h, 144 hour initial exposure; 24 h, 24 hour initial exposure; P1, passage 1; P5, passage 5; P10, passage 10; NT, not tested.
*Represents a MIC fold lower than the baseline value.
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suggested that shorter lag phases provide a selective
advantage (Sleight and Lenski 2007). There were instances
where growth whilst in the presence of antibiotic was
delayed (i.e. bacitracin and S. aureus; neomycin and S.
pyogenes). It has been inferred that an elongated lag phase
provides adaptive survival advantages and promotes
regrowth upon the removal of an antibiotic (Li et al.
2016).
Our findings question the validity of continued use
(inclusion in topical OTC products) of neomycin, due to
the extreme stable increase in MIC observed, tyrothricin
and bacitracin for their potential to cause stable changes
in MIC and cross-resistance to un-related antibiotics.
Gramicidin as a topical antibiotic is used for its activity
against Gram-positive micro-organisms (Swierstra et al.
2016; Berditsch et al. 2019), for this reason, S. aureus
growth and change in antibiotic cross-susceptibility at the
concentration of gramicidin used in common practice is
concerning. Staphylococcus aureus resistance to Grami-
cidin S has been previously reported and attributed to
consolidation and thickening of the cell wall (Orlova
et al. 2007). These findings compliment the conclusions
of a recent review that found inconclusive evidence that
the use of these four antibiotics (bacitracin, gramicidin,
neomycin and tyrothricin) for sore throat was beneficial
(Essack et al. 2019). Furthermore, the review concluded
that it was not possible to predict the impact of use on
antimicrobial resistance.
The outcome of our study warrants further investiga-
tion into the difference between the in-use and during-
use antibiotic exposure concentration and their effect on
the susceptibility and cross-susceptibility of common
pathogens. Furthermore, our findings reinforce concern
about the over-use and misuse of antibiotics and provide
evidence to support enforcement of the WHO action
plan (WHO 2013, 2015, 2018) and the global drive to
tackle antibiotic resistance. O’Neill (2016) estimated that
in the US and Europe alone, resistant infections cause at
least 50 000 deaths per year. In accordance with the
WHO action plan (WHO 2015) it is vital that the pre-
scribing of antibiotics is regulated prudently and the pub-
lic be educated and informed on the risks of self-
medication. The consumption of antibiotics needs to be
better controlled. Further restriction on the use of these
Table 4 MIC changes after exposure and passage in antibiotics or broth only. Values in bold represents an MIC higher than the baseline MIC
MIC
Tyrothricin (mg ml1) Gramicidin (mg ml1) Neomycin (mg ml1) Bacitracin (U)
Antibiotic Broth only Antibiotic Broth only Antibiotic Broth only Antibiotic Broth only
Staphylococcus aureus
144 h NT NT No change NT NT 125  0
P1 250  0 125  0
P5 MIC remained >30  0 >250  0 65  0
P10 >250  0 65  0
Streptococcus pyogenes
144 h NT NT NT NT 063  000 NT NT
P1 25  0 016  000
P5 25  0 016  000
P10 25  0 016  000
Acinetobacter baumannii
24 h No change No change No change 125  0
P1 No growth 250  0 250  0
P5 250  0 250  0
P10 250  0 250  0
Klebsiella pneumoniae
24 h 002  000 NT NT NT NT NT NT
P1 208  072 25  00
P5 25  00 25  00
P10 25  00 25  00
Pseudomonas aeruginosa
24 h >5  0 No change NT NT NT NT
P1 No growth
P5
P10
144 h, 144 hour initial exposure; 24 h, 24 hour initial exposure; P1, passage 1; P5, passage 5; P10, passage 10; NT, not tested.
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antibiotics in OTC medicine for sore throat seem neces-
sary to manage antimicrobial resistance and to reduce it
as much as possible.
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